Personalized stent treatment.

Transcription

1 Personalized stent treatment.

2 2 is an early-stage medical device start-up. develops a breakthrough remote and in situ monitoring technology (patent pending) that can equip all stents turning them into connected healthcare devices. is protected from competitors by patents and a unique know-how. aims to save 1 patient every 15 min. is driven by a multi-disciplinary team. is supported by world class scientific, medical and business advisors. offers a 2 B opportunity in an innovation-driven market. is laureate of the World Innovation Competition, the i-lab competition, the Hello Tomorrow Challenge, the JL Gerondeau/Zodiac Aerospace Prize and Tremplin Entreprises. is seeking 1.4M (0.4M remain) seed funding to go to first-inanimal.

3 3 Stents are designed to prevent heart attacks Blood-thinner

4 Limited information: 1 death/15 min 4 Stent in artery Blood clot in stent 50 % survival rate

5 5 How long should the blood-thinner treatment last? More than 12 months? Less than 6 months? Stent thrombosis has only a 50% survival rate! High risk patient population > 25% Major bleeding has an increased mortality risk! High risk patient population > 15% Mauri Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents, N Engl J Med 2014

6 Doctors explicitly express their need 2013 The optimum duration of DAPT after coronary stenting is unknown and depends on individual patient and procedural criteria. The PARIS registry shows a pronounced heterogeneity of treatment patterns and risk in patients who discontinue DAPT. CURRENT ATHEROSCLEROSIS REPORTS Sep 2015 Importantly, a one-size-fits-all approach to guide DAPT duration is likely to oversimplify what is a rather more complex clinical decision. More than 30 articles in 2015 alone (PubMed) 6

7 Instent monitors healing process in situ 7

8 First smart stent prototype in action 8

9 Two successful animal trials in

10 10 Instent s sensor characterizes the stent s in situ environment: key to monitoring healing endothelial cells no cells blood clot smooth-muscle cells

11 Smart stent data benefits all stakeholders and leads to a safer and more cost-efficient treatment Accompanied life-style changes Better compliance due to a better understanding of the disease Optimized pooling of patient risk Increased efficiency of the healthcare system Online stent implantation procedure feedback Improved understanding of disease pathology Tailored & preventive treatment Increased market share Reduced development cost 11

12 Stent market expected to reach 8 billion 12 9% 3% % 10% Annual growth rate Market breakdown 2014 Sources: Coronary Stents - Global Trends, Estimates and Forecasts, , Axis Research Mind, 2014 Global Coronary Stents Market (Drug Eluting & Bare Metal) Is Expected To Reach USD 8.3 Billion By 2016, Transparency Market Research, 2013

13 US stent market share Innovators own the market 13 60% 50% J&J Cordis Boston Scientific 40% 30% Medtronic Abbott 20% 10% * Other 0% Bare metal stents 1 st generation 2 nd generation drug-eluting stents drug-eluting stents Sources: Leerink & assumption of stable BMS market since 2004

14 14 and experienced business mentors Franz Bozsak, PhD CEO & co-founder Stent technology expert Stanford Ignite Graduate Abdul Barakat, PhD CSA & co-founder Biomechanics & atherosclerosis expert AXA Chair holder Yvan Bonnassieux, PhD Ecole polytechnique Pioneer in organic electronics Sacha Loiseau, PhD CEO & founder, Mauna Kea Technologies Bruno Carreel R&D manager & CTO Myline Cottance, PhD R&D manager Bruno Le Pioufle, PhD ENS Cachan Florian Reinaud, MD Medical entrepreneur Micro-electronics expert Manufacturing expert Expert in biosensors Pierluca Messina, PhD R&D manager Sensor expert Gor Lebedev, PhD R&D manager Analysis & simulation expert Antoine Lafont, MD, PhD Hôpital européen Georges-Pompidou, co-founder ART Eric Le Royer MedTech entrepreneur & Industry expert Top 5 interventional cardiologist in France Nathalie Bufi, PhD Operations manager Ulrich Sigwart, MD, PhD emer. University of Geneva Gonzague Issenmann MedTech entrepreneur & Industry expert Pioneer of vascular stenting

15 Instent s milestones to market 15 Q3 19 EU market entry Q4 17 First-in-human Q4 16 First-in-animal

16 The stent is only the beginning 16

17 17 A breakthrough technology (patent pending) aligned with current and future trends in healthcare (connected health, big data, reduced healthcare costs). A well-networked team with world-class scientific, medical and business advisors. A 2 B opportunity in an innovation-driven market. Prototyping phase under way in best-in-class environment at Ecole polytechnique. Company is seeking seed money to leverage significant non-dilutive funding from various sources. contact@instent.eu Follow us on /instent_